Area of research
Rheumatology · Surgery
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Lipoproteins and Cardiovascular Health, and Systemic Lupus Erythematosus Research.
Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with RA: a randomized controlled trial.
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis.
2025 ESC Guidelines for the management of myocarditis and pericarditis.
Cardiovascular risk factors management in older adults: a clinical consensus statement from the European Association of Preventive Cardiology of the ESC and the ESC Council for Cardiology Practice
<i>European Journal of Heart Failure</i> Consensus Statement. Heart Failure Pharmacotherapy for Patients with Heart Failure with Reduced Ejection Fraction and Concomitant Atrial Fibrillation: Review of Evidence and Call to Action
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use.
From consensus to action: Implementing cardiovascular prevention guidelines in primary healthcare
Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study.
2024 ESC Guidelines for the management of chronic coronary syndromes.
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial.
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
Rheumatoid arthritis and the risk of ischaemic stroke after diagnosis of atrial fibrillation: a Norwegian nationwide register study.
All about clinical trials
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.
Cardiovascular organ damage in relation to hypertension status in patients with ankylosing spondylitis.
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction.
Advancing medical education-a brief report by the ESC Working Group on Cardiovascular Pharmacotherapy.
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment.
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit.
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy